Seeking Alpha

Seeking Alpha Portfolio App for iPad

2,052 people get CHTP articles and Market Currents by email alert.

Get email alerts on CHTP »

CHTP

Chelsea Therapeutics International, Ltd.

5/22/2013, 7:24 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 2, 5:57 AM Chelsea Therapeutics (CHTP): Q1 EPS of -$0.06 misses by $0.01. (PR) 2 Comments [Earnings, Breaking News, Healthcare]
Wednesday, March 27, 9:25 AM Premarket gainers: CHCI +51%. UTSI +23%. STSI +14%. VELT +12%. CHTP +11%.
Losers: ASTM -37%. CLF -14%. GV -7%. LNDC -6%. Comment! [On the Move]
Wednesday, March 27, 8:51 AM Chelsea Therapeutics (CHTP) shares jump 13.3%, possibly due to SA author Shane Blackman predicting that shares could double over the next nine months after the FDA effectively indicated that the company's Northera drug is a shoe-in for approval in late 2013 or Q1 2014. 1 Comment [Healthcare, On the Move]
Thursday, March 7, 5:03 PM Chelsea Therapeutics (CHTP): Q4 EPS of -$0.03 beats by $0.05. Shares -1.1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Wednesday, February 20, 2:42 PM Shares of Chelsea Therapeutics (CHTP +141%) continue to soar higher on earlier reports of positive FDA feedback and resubmission guidance on its Northera study. Based on the input, Chelsea plans to file a resubmission of the Northera NDA with the DCRP late in Q213. If accepted, the application will be subject to a 6-month review period. 2 Comments [Healthcare, On the Move]
Wednesday, February 20, 8:10 AM Chelsea Therapeutics (CHTP +103%) surges after the FDA says the company's Study 306B of its Northera treatment for hpotension has "the potential to serve as the basis for a resubmission" of a New Drug Application for the medicine. Chelsea has been on a roller coaster ride since the summer, when the FDA said studies were unlikely to to provide enough evidence to support marketing approval for Northera. (PR) 1 Comment [Healthcare, On the Move]
Friday, December 7, 2012, 12:50 PM Midday top 10 gainers: CBMX +184%. GTIM +48%. LTBR +18%. DLGC +17%. RECV +16%. UNXL +15%. PAMT +15%. TELK +14%. JKS +14%. XPLR +11%.
Midday top 10 Losers: TOPS -23%. AMRN -19%. KUTV -15%. VTSS -13%. MBLX -11%. CHLN -11%. CHTP -9%. RGC -8%. CUR -8%. AACC -8%. Comment! [On the Move]
Wednesday, December 5, 2012, 12:45 PM Midday top 10 gainers: MMR +82%. EBOD +69%. MBLX +32%. PXP +26%. UEPS +25%. MITK +23%. AVAV +16%. CYCC +15%. CIE +15%. PLAB +13%.
Midday top 10 Losers: CHTP -36%. LORL -35%. TIBX -21%. MFRM -21%. ANIK -20%. SINO -19%. BLIN -18%. P -17%. THQI -17%. FIZZ -15%. 1 Comment [On the Move]
Wednesday, December 5, 2012, 9:10 AM Premarket gainers: MMR +77%. PXP +25%. PPHM +21%. CIE +13%. UEPS +12%. OCZ +10%. FRAN +9%. SSRI +9%. EXXI +8%. TEA +7%.
Losers: CHTP -31%. MFRM -20%. MIND -17%. P -15%. FCX -14%. TIBX -13%. JRCC -11%. Comment! [On the Move]
Tuesday, December 4, 2012, 5:04 PM Chelsea Therapeutics (CHTP) craters in spite of announcing positive preliminary results for Study 306B, a Phase III trial of Northera, a treatment for hypotension associated with Parkinson's Disease, saying the trial met its primary endpoint. The devil lies in the details however, as investors react to the results under the shadow of the FDA's earlier statement that the trial was unlikely to provide sufficient confirmatory evidence to support an NDA. Shares -22% AH. 2 Comments [Healthcare, On the Move]
Tuesday, November 6, 2012, 9:52 AM Chelsea Therapeutics' (CHTP) Northera drug increased blood pressure in patients with spinal chord injuries and hypotension (low blood pressure) in a study. Increasing blood pressure is important, as hypotension has been "linked to deficits in memory and attention processing," says one of the trial's authors. Northera is the lead investigational drug in Chelsea's pipeline and is in Phase III trials. (PR) 1 Comment [Healthcare]
Thursday, October 25, 2012, 12:45 PM Midday top 10 gainers: PSSI +33%. PRLB +20%. CHTP +20%. NYMX +17%. TEN +16%. SPRT +15%. DDD +15%. OSTK +14%. VRS +13%. LOGM +13%.
Top 10 Losers: SPR -31%. BBW -25%. DEXO -23%. PACR -20%. CROX -19%. TBI -17%. LOGI -16%. DFT -15%. NYT -14%. SQNS -13%. Comment! [On the Move]
Tuesday, July 10, 2012, 9:10 AM Premarket gainers: VRNG +11%. ASML +8%. CALL +7%. GEVA +5%.
Losers: MAKO -40%. JRCC -17%. AMBT -11%. BZH -9%. AMD -9%. CHTP -7%. AMAT -6%. Comment! [On the Move]
Tuesday, July 10, 2012, 8:25 AM Chelsea Therapeutics (CHTP -4.8%) CEO Simon Pedder quits with immediate effect, and the company says its intends to "significantly reduce" its workforce and explore strategic options. The drama comes a week after the FDA requested another trial for Chelsea's hypotension drug Northera. (PR) Comment! [On the Move, Healthcare]
Friday, July 6, 2012, 11:24 AM Chelsea Therapeutics (CHTP +33%) soars today on the back of a Seeking Alpha article this morning that says the drug developer could see "Arena-like" gains off Northera. The stock was hit hard earlier when the FDA recommended further trials for the drug and consequently has built up a large short interest over a short period. The article says investors are ignoring the millions of dollars put into R&D on the drug, and once they realize it's undervalued, it's going be off to the races. 1 Comment [Healthcare, On the Move]
Tuesday, July 3, 2012, 9:25 AM Chelsea Therapeutics (CHTP) -51.4% premarket after the drug developer is notified by the FDA that data from the continuing study of its Northera low-blood-pressure medication, the company's lead drug candidate, is unlikely to provide enough evidence to support marketing approval for the treatment. Comment! [Healthcare, On the Move]